369 related articles for article (PubMed ID: 27715380)
21. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
[TBL] [Abstract][Full Text] [Related]
22. [Uveitic glaucoma in Behçet's disease: When everything gets complicated].
Belkhadir K; Boutimzine N; Tachfouti S; Laghmari M; Amazouzi A; Cherkaoui O
J Fr Ophtalmol; 2020 Sep; 43(7):635-641. PubMed ID: 32622636
[TBL] [Abstract][Full Text] [Related]
23. Uveitis in Behçet disease in a tertiary center over 25 years: the KKESH Uveitis Survey Study Group.
Arevalo JF; Lasave AF; Al Jindan MY; Al Sabaani NA; Al-Mahmood AM; Al-Zahrani YA; Al Dhibi HA; ;
Am J Ophthalmol; 2015 Jan; 159(1):177-84.e1-2. PubMed ID: 25448998
[TBL] [Abstract][Full Text] [Related]
24. Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Behcet's disease.
Gedik S; Akova Y; Yilmaz G; Bozbeyoğlu S
Ocul Immunol Inflamm; 2005 Feb; 13(1):51-8. PubMed ID: 15804770
[TBL] [Abstract][Full Text] [Related]
25. Macular ischaemia in Behçet's disease.
Yilmaz G; Akova Y; Aydin P
Eye (Lond); 2000 Oct; 14 Pt 5():717-20. PubMed ID: 11116691
[TBL] [Abstract][Full Text] [Related]
26. Visual outcome in ocular sarcoidosis: retrospective evaluation of risk factors.
Miserocchi E; Modorati G; Di Matteo F; Galli L; Rama P; Bandello F
Eur J Ophthalmol; 2011; 21(6):802-10. PubMed ID: 21374555
[TBL] [Abstract][Full Text] [Related]
27. Eye and Behçet's disease.
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Apr; 42(4):e133-e146. PubMed ID: 30850197
[TBL] [Abstract][Full Text] [Related]
28. Clinical features of chinese patients with Behçet's disease.
Yang P; Fang W; Meng Q; Ren Y; Xing L; Kijlstra A
Ophthalmology; 2008 Feb; 115(2):312-318.e4. PubMed ID: 17692378
[TBL] [Abstract][Full Text] [Related]
29. Ocular Manifestations in Late Onset Behçet's Disease.
Saadouli D; Mansour KB; Yahyaoui S; Afrit NE; Lahmar A; Afrit AE
Curr Aging Sci; 2021; 14(1):56-61. PubMed ID: 31994475
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic factors of ocular involvement in Behçet's disease].
Belkhadir K; Boutimzine N; Laghmari M; Amazouzi A; Tachfouti S; Cherkaoui O
J Fr Ophtalmol; 2019 Jun; 42(6):612-617. PubMed ID: 31088739
[TBL] [Abstract][Full Text] [Related]
31. Functional and morphological changes in the eyes of Behçet's patients with uveitis.
Takeuchi M; Iwasaki T; Kezuka T; Usui Y; Okunuki Y; Sakai J; Goto H
Acta Ophthalmol; 2010 Mar; 88(2):257-62. PubMed ID: 19489762
[TBL] [Abstract][Full Text] [Related]
32. [Ocular manifestations in Behçet's disease].
Zeghidi H; Saadoun D; Bodaghi B
Rev Med Interne; 2014 Feb; 35(2):97-102. PubMed ID: 24290834
[TBL] [Abstract][Full Text] [Related]
33. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease.
Bae JH; Lee SC
Retina; 2012 Jul; 32(7):1395-402. PubMed ID: 22012204
[TBL] [Abstract][Full Text] [Related]
34. [Epidemiological, clinical, therapeutic and evolutionary profile of ocular manifestations in patients with Behçet's disease].
Razzak A; Kassimi A; Mchachi A; Benhmidoune L; Chakib A; Rachid R; Elbelhadji M; Amraoui A; Elkabli H
Pan Afr Med J; 2019; 33():116. PubMed ID: 31489094
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease.
Atmaca LS; Yalçindağ FN; Ozdemir O
Graefes Arch Clin Exp Ophthalmol; 2007 Mar; 245(3):451-6. PubMed ID: 17226025
[TBL] [Abstract][Full Text] [Related]
36. Long-term progression of retinal vasculitis in Behçet patients using a fluorescein angiography scoring system.
Kang HM; Lee SC
Graefes Arch Clin Exp Ophthalmol; 2014 Jun; 252(6):1001-8. PubMed ID: 24796770
[TBL] [Abstract][Full Text] [Related]
37. Behçet's disease ocular attack score 24 and visual outcome in patients with Behçet's disease.
Tanaka R; Murata H; Takamoto M; Ohtomo K; Okinaga K; Yoshida A; Kawashima H; Nakahara H; Fujino Y; Kaburaki T
Br J Ophthalmol; 2016 Jul; 100(7):990-994. PubMed ID: 26553921
[TBL] [Abstract][Full Text] [Related]
38. Asymptomatic Progression of Ocular Behçet's Disease.
Roizenblatt M; Fares N; Nascimento H; Novais EA; Muccioli C; Belfort R
Ophthalmic Surg Lasers Imaging Retina; 2017 Jan; 48(1):18-35. PubMed ID: 28060390
[TBL] [Abstract][Full Text] [Related]
39. [Intravenous corticosteroid megadose treatment in ocular Behçet disease].
Postelmans L; Verougstraete C; Libert J; Efira A; Caspers-Velu L
Bull Soc Belge Ophtalmol; 1996; 262():95-103. PubMed ID: 9376926
[TBL] [Abstract][Full Text] [Related]
40. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years.
Davatchi F; Sadeghi Abdollahi B; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Faezi T; Akhlaghi M; Ghodsi Z; Ashofteh F; Mohtasham N
Int J Rheum Dis; 2014 May; 17(4):444-52. PubMed ID: 24314325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
